Health ❯ Pharmaceuticals ❯ Drug Approval

Clinical Trials

Safety Regulations Gene Therapy Prader-Willi Syndrome Merck Tezspire Koselugo Genetic Disorders Side Effects

Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Class Action

Filings claim the company downplayed FDA objections to relacorilant by touting its approval prospects.

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

FDA Rejects Disc Medicine’s Bitopertin for EPP After Questioning Surrogate Endpoint

EU Panel Backs Tezspire for Chronic Rhinosinusitis With Nasal Polyps

FDA Advisers Recommend Against Approval of GSK’s Myeloma Drug Blenrep

FDA Approves VYKAT XR, First Therapy for Hyperphagia in Prader-Willi Syndrome